|Videos|July 27, 2016

What Factors Contribute to the Virulence of Staph aureus?

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, examines the virulence factors of Staphylococcus aureus.

Jeff Boyd, PhD, assistant professor of Biochemistry and Microbiology at Rutgers School of Environmental and Biological Sciences, examines the virulence factors of Staphylococcus aureus.

Interview Transcript (slightly modified for readability).

“Some factors that would contribute to virulence and Staphylococcus aureus include different things such as the ability to form a capsule. A capsule [is] a layer, or a slime layer, on the outside of the cell which prevents phagocytosis by white blood cells or prevents recognition by antibodies.

Staph makes another protein called “Protein A,” which binds to human antibodies on the outside of the cell, and it masks and coats it with human antibodies so the immune system can’t recognize it. Staph aureus has the ability to make a number of different toxins which can lice white blood cells [and] red blood cells. It has the ability to acquire nutrients that might be hard or limiting in the human body, such as iron. Staph can produce a toxin which will lice red blood cells and then it has a mechanism to get heme out of hemoglobin and use that iron as a source of iron for the cell to grow.

Staph aureus also has the ability to produce a number of superantigens. One you might have heard of include toxic shock syndrome toxin. These will stimulate or cause the human immune system to overreact to the presence of Staph aureus, or the presence of this toxin, and can cause the body to have a number of global metabolic defects and ultimately, if untreated, will lead to death.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.